'Seena' clinical trials named for pancreatic cancer advocate
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.
Pancreatic cancer patients can soon enroll in Seena I, which is planned for at least four clinical sites across the nation, including Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare.
The Pancreatic Cancer Research Team (PCRT) will supervise the Seena trials. PCRT is a worldwide consortium of 45 clinical institutions led by TGen and dedicated to finding a cure for pancreatic cancer.
For nearly a decade, Scottsdale resident Roger Magowitz has championed research into finding a cure for pancreatic cancer, a disease that took the life of his mother, Seena, in 2001.
"I am deeply honored and filled with tremendous hope that the clinical trials named for my mother, Seena, will lead perhaps within just a few years to an actual cure for pancreatic cancer," said Roger Magowitz, President of the Seena Magowitz Foundation, who has donated $1 million to the TGen pancreatic cancer initiative.
The pancreas is a gland behind the stomach that secretes enzymes into the upper part of the small intestine to help digestion. It also produces hormones, including insulin, which helps regulate the metabolism of sugars.
The Seena I trial consists of three treatment components:
- The first treatment will be with gemcitabine and nab-paclitaxel (Abraxane) for a maximum of 6 months.
- The next treatment is with a combination of four drugs: 5-FU (fluoruracil); Leucovorin; Oxaliplatin; and Irinotecan. This combination is called FOLFIRINOX, an acronym of all drugs combined. Patients will be given this treatment for a maximum of 6 months.
- In the third treatment, the patient's tumor will be biopsied and analyzed using molecular profiling to determine the next most appropriate treatment. Patients also will receive a drug called Metformin during this part of the study.
The clinical trial sites includes the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare, where the principal investigator is TGen Physician-In-Chief Dr. Daniel Von Hoff, one of the world's leading authorities on pancreatic cancer. Dr. Von Hoff also is chief scientific officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
Dr. Von Hoff said that TGen, through the Virginia G. Piper Cancer Center at Scottsdale Healthcare and its other PCRT partners, are making progress in the quest to end this cancer: "We are to deliver a knockout punch by combining the best treatments we have against the disease. The contributions of Roger Magowitz represent significant acceleration toward our goal of finding better treatments, and ultimately a cure."
The other clinical trial sites are:
Virginia Piper Cancer Institute, Minneapolis, Minn., where the principal investigator is Dr. John Seng: "We are one of the nation's leading pancreatic cancer treatment centers. The new Seena clinical trial will allow patients to take a more active role in their health care, gain access to new drugs, treatments and disease management practices, and contribute to medical research."
Evergreen Hematology & Oncology, Spokane, Wash., where the principal investigator is Dr. Stephen Anthony: "As the former Chief Medical Officer of TGen Drug Development, I know how meticulously this study will be organized and conducted, using every efficiency possible to reach patients with the safest and most effective compounds possible."
Roy and Patricia Disney Family Cancer Center, Burbank, Calif., where the principal investigator is Dr. Peter Rosen: "The Roy and Patricia Disney Family Cancer Center brings innovative clinical trials to the San Fernando Valley, an underserved population of close to 3 million inhabitants. In addition to Phase I (drug development) trials and an Adolescent and Young Adult (AYA) program, we are committed to a frontal attack on pancreas cancer, the nation's fourth leading cause of cancer mortality. The Seena trial exemplifies that commitment."
Provided by The Translational Genomics Research Institute
- New investigational compound targets pancreatic cancer cells Sep 15, 2010 | not rated yet | 0
- Results of new drug for pancreatic cancer patients published Oct 04, 2011 | not rated yet | 0
- TGen, Virginia G. Piper Cancer Center studying new breast cancer drug Jul 20, 2011 | not rated yet | 0
- TGen Foundation launches 'globalCure,' targets pancreatic cancer Mar 10, 2011 | not rated yet | 0
- Effort aims to spike breast cancer with new approach Mar 11, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
13 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...
Cancer 33 minutes ago | not rated yet | 0 |
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...
Cancer 4 hours ago | not rated yet | 0
Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.
Cancer 5 hours ago | not rated yet | 0 |
Frequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data ...
Cancer 5 hours ago | not rated yet | 0
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
1 hour ago | not rated yet | 0 |
Finnish researchers unveiled new data Thursday to link the Pandemrix flu vaccine to a higher risk of the sleeping disorder narcolepsy in adults.
33 minutes ago | not rated yet | 0
Maintaining a heart healthy lifestyle may also help protect chronic kidney disease patients from developing kidney failure and dying prematurely, according to a study appearing in an upcoming issue of the Journal of the Am ...
3 minutes ago | not rated yet | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
23 minutes ago | not rated yet | 0
The Senate has overwhelmingly rejected an amendment allowing states to require labeling of genetically modified foods.
13 minutes ago | not rated yet | 0
A second child has contracted polio in a restive Pakistani tribal region near the Afghan border after the Taliban banned vaccinations there nearly a year ago, a UN official said Thursday.
53 minutes ago | not rated yet | 0